Catherine Sohn - Jazz Pharmaceuticals Director
| J7Z Stock | EUR 100.95 2.40 2.32% |
Director
Dr. Catherine Angell Sohn, Pharm.D., CLP, is an a Independent Director of Jazz Pharmaceuticals Plc. Dr. Sohn has served as a member of our board of directors since July 2012 and was appointed as chairperson of our nominating and corporate governance committee in August 2013. Since January 2014, Dr. Sohn has served as an independent director on the board of directors of Neuralstem, Inc., a publiclytraded life sciences company, where she is currently serving as Chairperson of the nominating and corporate governance committee. Since November 2012, Dr. Sohn has also served as an independent director on the board of directors of Landec Corporationrationration, a publiclytraded life sciences company, where Dr. Sohn is currently serving as Chairperson of the compensation committee. From 1998 to 2010, she was Senior Vice President, Worldwide Business Development and Strategic Alliances at GlaxoSmithKline Consumer Healthcare. From 1994 to 1998, she was Vice President, Worldwide Strategic Product Development at SmithKline Beecham Pharmaceuticals plc in the pharmaceutical division. From 1982 to 1994, she held a series of positions in Medical Affairs, Pharmaceutical Business Development and U.S. Product Marketing at SmithKline Beecham Pharmaceuticals plc and its predecessor, Smith, Kline French. Dr. Sohn holds the positions of Adjunct Professor at the University of California, San Francisco and Deans Professor at the University of the Sciences in Philadelphia. She received a Doctor of Pharmacy from the University of California, San Francisco, School of Pharmacy and a Certificate of Professional Development from the Wharton School at the University of Pennsylvania. Dr. Sohn was named Woman of the Year by the Healthcare Businesswomens Association and Distinguished Alumnus of the Year by the University of California, San Francisco and is a Certified Licensing Professional and a National Association of Corporationrationrate Directors Board Leadership Fellow. since 2012.
| Age | 65 |
| Tenure | 12 years |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Kreger | NorAm Drilling AS | 33 | |
| Craig Jacobson | NorAm Drilling AS | 65 | |
| David Smith | Superior Plus Corp | 59 | |
| Randall Findlay | Superior Plus Corp | 67 | |
| Catherine Best | Superior Plus Corp | 64 | |
| Eugene Bissell | Superior Plus Corp | 64 | |
| Walentin Mirosh | Superior Plus Corp | 71 | |
| James Arestia | NorAm Drilling AS | N/A | |
| Robert Engbloom | Superior Plus Corp | 64 | |
| Ross Levinsohn | NorAm Drilling AS | 54 | |
| Patrick Gottschalk | Superior Plus Corp | 54 | |
| Peter Murphy | NorAm Drilling AS | 55 | |
| Laura Walker | NorAm Drilling AS | 60 | |
| Mary Jordan | Superior Plus Corp | 58 | |
| Peter Kern | NorAm Drilling AS | 50 | |
| Richard Bradeen | Superior Plus Corp | 61 | |
| Douglas Harrison | Superior Plus Corp | 58 | |
Management Performance
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 |
Jazz Pharmaceuticals plc Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diane Schrick, Senior Director, Investor Relations | ||
| Matthew Young, CFO, Senior Vice President | ||
| Finbar Larkin, VP Operations | ||
| Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World | ||
| Rick Winningham, Independent Director | ||
| Peter Gray, Non-Executive Director | ||
| Katherine Littrell, Vice President - Investor Relations | ||
| Paul Treacy, Senior Vice President Technical Operations | ||
| Renee Gala, Ex CFO | ||
| Robert MD, Ex RD | ||
| Robert Iannone, Executive Vice President Research and Development | ||
| Karen Wilson, Vice President - Finance, Principal Accounting Officer | ||
| Seamus Mulligan, Independent Director | ||
| Russell Cox, Chief Commercial Officer, Executive Vice President | ||
| Karen Smith, Global Head of Research & Development and Chief Medical Officer | ||
| Neena JD, Ex Officer | ||
| George Eliades, Sr Officer | ||
| Paul Berns, Independent Director | ||
| Daniel Swisher, President COO | ||
| Anne ORiordan, Director | ||
| Suzanne Hooper, Executive Vice President General Counsel | ||
| Patricia Carr, VP Officer | ||
| Heather McSharry, Director | ||
| Michael Miller, Senior Vice President - U.S. Commercial | ||
| Andrea Flynn, VP Relations | ||
| Patrick Enright, Independent Director | ||
| Norbert Riedel, Director | ||
| Catherine Sohn, Director | ||
| Heidi Manna, VP Officer | ||
| Elmar Schnee, Independent Director | ||
| Kenneth OKeefe, Independent Director | ||
| Bruce Cozadd, Chairman of the Board, CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |